Association of Germiline BRCA Pathogenic Variants with Diminished..
Survival with Cemiplimab in Recurrent Cervical Cancer
Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial
NItrogen-based bisphosphonate use ad ovarian cancer risk in women aged 50 years and older